Total pharma industry M&A deals in April 2019 worth $4.1bn were announced globally, according to GlobalData’s deals database.
The value marked an increase of 45.02% over the previous month and a drop of 82.1% when compared with the last 12-month average, which stood at $22.93bn.
Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $3.35bn. At the country level, the US topped the list in terms of deal value at $3.33bn.
In terms of volumes, North America emerged as the top region for pharma industry M&A deals globally, followed by Europe and then Asia-Pacific.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
The top country in terms of M&A deals activity in April 2019 was the US with 20 deals, followed by the UK with six and Germany with four.
In 2019, as of the end of April 2019, pharma M&A deals worth $140.39bn were announced globally, marking a decrease of 9.9% year on year.
Pharma industry M&A deals in April 2019: Top deals
The top five pharma industry M&A deals accounted for 89.6% of the overall value during April 2019.
The combined value of the top five pharma industry M&A deals stood at $3.67bn, against the overall value of $4.1bn recorded for the month. The top announced pharma industry M&A deal tracked by GlobalData in April 2019 was Novartis’ $1.58bn acquisition of IFM Tre.
In second place was the $1.2bn acquisition of Paragon Bioservices by Catalent and in third place was Eddingpharm’s $375m asset transaction with Eli Lilly and.
The $264m asset transaction with Aronora by XOMA and RP Management’s asset transaction with Arteaus Therapeutics for $260m held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
Date: May 28, 2019
Source: Pharmaceutical Technology
